By Catie Wightman, Michelle Bodian
Nov 30, 2022
On November 21, 2022, the FDA issued five warning letters to companies selling CBD, Delta-8, and other hemp products for humans and pets.
By Yolanda Clarke, Jamie Greenwood
Nov 16, 2022
In another exciting step towards implementing psilocybin services, the Oregon Psilocybin Services Section issued updated proposed rules under the Oregon Psilocybin Services Act this month, making significant changes to the previous iteration. Make your voices heard! The public comment period is open through November 21, 2022.
By Jen Flanagan, Sam Kovach-Orr, Meg Nash, Bridgette Nikisher
Nov 16, 2022
Widespread support for allowing cannabis retail sales in Rhode Island municipalities significantly expands opportunities for potential applicants seeking to obtain one of the 24 cannabis retail licenses expected to be available in 2023. Read this article for insight into what to expect next and how to prepare.
By Michelle Bodian, Bridgette Nikisher
Nov 15, 2022
Who wants free money for investing in a Connecticut cannabis company? CT's Cannabis Angel Tax Credit Program provides a way for investors to receive a 25% tax credit against the state income tax when they invest at least $25k in an approved social equity cannabis licensee.
By Shane Pennington
Nov 9, 2022
What outcomes are possible from the impending administrative process to reconsider cannabis’s schedule I status? What are the implications of those various possible outcomes? And how should we all proceed in light of it all?
Commentary and analysis on cannabis, hemp, psychedelics, and other emerging therapies from the attorneys and policy specialists at the nation’s leading cannabis law firm.